Search

According to the discharge report, the patient presented comatose with hypersalivation and increased diaphoresis and was diagnosed to have respiratory failure, myoclonic status, disturbed carbohydrate metabolism, electrolyte disorders, and metabolic encephalopathy. Based on clinical and laboratory findings, severe cholinesterase inhibition was diagnosed and the patient was started on atropine and obidoxime (250 mg bolus followed by continuous administration of 750 mg per day). We gratefully acknowledge the support from many colleagues in the assessment and interdisciplinary management of this case, including members of the Bundeswehr Institute of Pharmacology and Toxicology in Munich, Germany, who did repetitive measurements of butyrylcholinesterase, acetylcholinesterase in red blood cells, and cholinesterase status and gave toxicological advice. 123, 2019, 457-463 4 H Thiermann, U Mast, R Klimmek, Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patients. [Extracted from the article]